We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+30.25%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$12B
AUM Growth
+$2.23B
Cap. Flow
-$2.3B
Cap. Flow %
-19.15%
Top 10 Hldgs %
76.74%
Holding
140
New
18
Increased
23
Reduced
51
Closed
10

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$121M
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$106M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$76.4M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$51.5M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$34.6M

Top Sells

Rank Stock Value
1
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$653M
2
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$73M
3
VNDA icon
Vanda Pharmaceuticals
VNDA
+$30.8M
4
PCYC
PHARMACYCLICS INC
PCYC
+$17.3M
5
XOMA
Xoma
XOMA
+$8.13M

Sector Composition

Rank Sector Weight
1 Healthcare 40.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCYC
1
DELISTED
PHARMACYCLICS INC
PCYC
$2.31B 19.24%
9,039,652
-89,579
-1% -$17.3M
INCY icon
2
Incyte
INCY
$25.3B
$1.36B 11.32%
14,845,559
– –
GEVA
3
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$1.14B 9.46%
11,660,432
+1,000,000
+9% +$106M
SGEN
4
DELISTED
Seagen Inc. Common Stock
SGEN
$1.02B 8.49%
28,876,712
+1,014,992
+4% +$34.6M
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$4.46B
$667M 5.55%
20,481,442
– –
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$12B
$523M 4.35%
4,200,456
+486,506
+13% +$51.5M
GHDX
7
DELISTED
Genomic Health, Inc.
GHDX
$417M 3.47%
13,656,942
+624
+0% +$19.8K
ANAC
8
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$243M 2.02%
4,204,702
– –
NVTA
9
DELISTED
Invitae Corporation
NVTA
$110M 0.91%
+6,554,967
New +$121M
ONCE
10
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$103M 0.86%
+1,327,451
New +$76.4M
DYAX
11
DELISTED
DYAX CORPORATION
DYAX
$101M 0.84%
6,021,485
-136,304
-2% -$2.12M
BLCM
12
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$97.1M 0.81%
419,059
-9,314
-2% -$2.25M
BCRX icon
13
BioCryst Pharmaceuticals
BCRX
$2.44B
$94.6M 0.79%
10,478,204
-235,482
-2% -$2.44M
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$82.2M 0.68%
2,805,074
+425,000
+18% +$9.97M
CERS icon
15
Cerus
CERS
$577M
$56.5M 0.47%
13,553,275
+1,850,548
+16% +$9.48M
ARAV
16
DELISTED
Aravive, Inc. Common Stock
ARAV
$54.7M 0.45%
496,233
+115,942
+30% +$13.6M
XOMA
17
DELISTED
Xoma
XOMA
$53.5M 0.45%
735,431
-110,770
-13% -$8.13M
XNPT
18
DELISTED
XENOPORT, INC.
XNPT
$46.3M 0.39%
6,508,622
-395,006
-6% -$3.06M
ARRY
19
DELISTED
Array Biopharma Inc
ARRY
$41.7M 0.35%
5,658,755
+4,224,958
+295% +$30.1M
HRTX icon
20
Heron Therapeutics
HRTX
$92.5M
$37.9M 0.32%
2,607,784
– –
DBVT
21
DBV Technologies
DBVT
$796M
$35.5M 0.3%
151,923
– –
INSM icon
22
Insmed
INSM
$22.5B
$32.9M 0.27%
1,583,490
+475,640
+43% +$8.38M
CPRX
23
DELISTED
Catalyst Pharmaceutical
CPRX
$32.8M 0.27%
7,565,462
+850,000
+13% +$3.06M
HALO icon
24
Halozyme
HALO
$9.87B
$32.1M 0.27%
2,248,152
-527,991
-19% -$7.61M
TGTX icon
25
TG Therapeutics
TGTX
$8.18B
$31.7M 0.26%
2,050,313
– –
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2015 Portfolio in Review

As of Q1 2015, Baker Bros. Advisors held 140 positions worth $12B, up 23% from $9.8B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Baker Bros. Advisors withdrew a net $2.3B in Q1 2015, closing 10 positions and reducing 51 holdings. Its most notable exit was AVANIR PHARMACEUTICALS, INC CL A, an estimated $653M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, down from 42% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in Invitae Corporation worth $110M.

  • Baker Bros. Advisors's largest Q1 2015 buy was Invitae Corporation: 6,554,967 shares worth $110M.
  • Baker Bros. Advisors added most to SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2015, an estimated $106M increase.
  • Baker Bros. Advisors's biggest Q1 2015 reduction was Vanda Pharmaceuticals, cutting an estimated $30.8M.
  • Baker Bros. Advisors fully exited AVANIR PHARMACEUTICALS, INC CL A in Q1 2015, selling an estimated $653M.
  • Baker Bros. Advisors's ten largest holdings make up 77% of its $12B portfolio in Q1 2015.
  • Baker Bros. Advisors opened 18 new positions and closed 10 in Q1 2015.
  • Baker Bros. Advisors's portfolio value rose 23% quarter-over-quarter to $12B.

Based on Baker Bros. Advisors's 13F filing for Q1 2015, filed 15 May 2015.